<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981968</url>
  </required_header>
  <id_info>
    <org_study_id>B1321046</org_study_id>
    <nct_id>NCT00981968</nct_id>
  </id_info>
  <brief_title>Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects</brief_title>
  <official_title>An Investigator- And Subjects- Blind Phase 1 Study To Investigate Pharmacokinetics, Safety And Tolerability Of Sitaxentan In Japanese Healthy Subjects Following Single And Multiple Doses And Western Healthy Subjects Following Single Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate safety, tolerability and pharmacokinetics of
      sitaxentan following single and multiple oral administrations of sitaxentan sodium in
      Japanese healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (spontaneous and solicited)</measure>
    <time_frame>Day 0 to Day 9 of Period 3 for cohort 1, Day 0 to Day 3 of Period 2 for cohort 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECGs, Vital signs, Safety laboratory test</measure>
    <time_frame>Screening visit to Day 9 of Period 3 for cohort 1 and Day 3 of Period 2 for cohort 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (single dose): Cmax, Tmax, AUC, t1/2, CL/F and V/F</measure>
    <time_frame>Day 1 of Periods 1 and 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (multiple dose): Cmax, Tmax, Ctrough, AUC, t1/2, CL/F, V/F, Rac and Rss</measure>
    <time_frame>Days 1 and 7 of Periods 1 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>No secondary outcome</measure>
    <time_frame>No secondary outcome</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Japanese Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single and multiple oral doses of sitaxentan sodium or placebo in 12 healthy subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Western Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of sitaxentan sodium in 10 healthy subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitaxentan sodium/Placebo</intervention_name>
    <description>100 mg and 200 mg, tablet, single and multiple oral doses for 7 days</description>
    <arm_group_label>Japanese Cohort</arm_group_label>
    <other_name>Thelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitaxentan sodium/Placebo</intervention_name>
    <description>100 mg and 200 mg, tablet, single oral dose</description>
    <arm_group_label>Western Cohort</arm_group_label>
    <other_name>Thelin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male and/or female subjects between the age of 18 and 55 years, inclusive.

        Body Mass Index of 17.5 to 33.5 kg/m2, and a total body weight &gt;45 kg. Mean body weight and
        the body weight range of Western subjects are similar to those of Japanese subjects with a
        10% plus and minus error.

        Exclusion Criteria:

        Pregnant or nursing females; females of childbearing potential who are unwilling or unable
        to use an acceptable method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1321046&amp;StudyName=Phase%201%2C%20single%20and%20multiple%20doses%20study%20of%20sitaxentan%20in%20Japanese%20and%20Western%20subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>October 14, 2010</last_update_submitted>
  <last_update_submitted_qc>October 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitaxsentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

